Lung cancer is the leading cause of cancer-related mortality. While the majority of lung
cancers are associated with tobacco smoke, approximately 10–15% of US lung cancers …

Early clinical studies of tyrosine kinase inhibitors (TKIs) that target the EGFR in patients with
advanced non-small-cell lung cancer (NSCLC) showed that some patients experienced …

Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …

Background Cisplatin-based adjuvant chemotherapy is the standard of care for patients with
resected stage II–IIIA non-small-cell lung cancer (NSCLC). RADIANT and SELECT trial data …

Introduction: PIONEER (NCT01185314) was a prospective, multinational, epidemiological
study of epidermal growth factor receptor (EGFR) mutations in patients from Asia with newly …

Background The phase III, randomized, open-label ENSURE study (NCT01342965)
evaluated first-line erlotinib versus gemcitabine/cisplatin (GP) in patients from China …

Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …

Specific mutations in epidermal growth factor receptor (EGFR) gene are predictive for
response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients …

The purpose of this article is to provide updated recommendations for the treatment of
patients with stage IV non–small-cell lung cancer. A literature search identified relevant …

Background A fusion gene between echinoderm microtubule-associated protein-like 4
(EML4) and the anaplastic lymphoma kinase (ALK) has recently been identified in non-small …